Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 283 articles:
HTML format
Text format



Single Articles


    March 2017
  1. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    PubMed     Text format     Abstract available


  2. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  3. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed     Text format    


  4. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Text format     Abstract available


  5. KOSINSKA AD, Pishraft-Sabet L, Wu W, Fang Z, et al
    Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models.
    Hepatology. 2017 Mar 13. doi: 10.1002/hep.29155.
    PubMed     Text format     Abstract available


  6. STELMA F, van der Ree MH, Sinnige MJ, Brown A, et al
    Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101.
    Hepatology. 2017 Mar 11. doi: 10.1002/hep.29148.
    PubMed     Text format     Abstract available


  7. HEZODE C, Colombo M, Bourliere M, Spengler U, et al
    Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29139.
    PubMed     Text format     Abstract available


    February 2017
  8. BELPERIO PS, Shahoumian TA, Mole LA, Backus LI, et al
    Evaluation of Hepatitis B Reactivation among 62,920 Veterans treated with Oral Hepatitis C Antivirals.
    Hepatology. 2017 Feb 27. doi: 10.1002/hep.29135.
    PubMed     Text format     Abstract available


  9. YAN F, Wang Y, Zhang W, Chang M, et al
    Human ES Cell-derived Hepatoblasts are an Optimal Lineage Stage for HCV Infection.
    Hepatology. 2017 Feb 25. doi: 10.1002/hep.29134.
    PubMed     Text format     Abstract available


  10. ZHANG W, Chen J, Wu M, Zhang X, et al
    PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interference with pgRNA Encapsidation.
    Hepatology. 2017 Feb 25. doi: 10.1002/hep.29133.
    PubMed     Text format     Abstract available


  11. LAWITZ E, Poordad F, Wells J, Hyland RH, et al
    Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130.
    PubMed     Text format     Abstract available


  12. HOGAN JJ, Lim MA, Palmer MB, Bloom RD, et al
    Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1).
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29125.
    PubMed     Text format     Abstract available


  13. SABERI B, Dadabhai AS, Durand CM, Philosophe B, et al
    Challenges in Treatment of Hepatitis C among Patients with Hepatocellular Carcinoma.
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29126.
    PubMed     Text format    


  14. XU L, Wang W, Li Y, Zhou X, et al
    RIG-I Is A Key Antiviral Interferon-Stimulated Gene Against Hepatitis E Virus Dispensable Of Interferon Production.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29105.
    PubMed     Text format     Abstract available


  15. LEMPP FA, Wiedtke E, Qu B, Roques P, et al
    Sodium taurocholate cotransporting polypeptide is the limiting host factor of Hepatitis B Virus infection in macaque and pig hepatocytes.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29112.
    PubMed     Text format     Abstract available


  16. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Text format     Abstract available


  17. CHEN G, Wang C, Chen J, Ji D, et al
    Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29109.
    PubMed     Text format     Abstract available


  18. DENOLLY S, Cosset FL
    A master regulator of tight junctions involved in hepatitis C virus entry and pathogenesis.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29066.
    PubMed     Text format    


  19. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


  20. CARTER L, Aronsohn A
    Overcoming Injustice: A Roadmap to Improve Access to HCV Therapy for Our Medicaid Patients.
    Hepatology. 2017 Feb 4. doi: 10.1002/hep.29095.
    PubMed     Text format    


  21. OLIVEIRA C, Fournier C, Descamps V, Morel V, et al
    Apolipoprotein(a) Inhibits Hepatitis C Virus Entry Through Interaction With Infectious Particles.
    Hepatology. 2017 Feb 2. doi: 10.1002/hep.29096.
    PubMed     Text format     Abstract available


    January 2017
  22. PAUL S, Dickstein A, Saxena A, Terrin N, et al
    Role of Surface Antibody in Hepatitis B Reactivation in Patients with Resolved Infection and Hematologic Malignancy: A Meta-Analysis.
    Hepatology. 2017 Jan 27. doi: 10.1002/hep.29082.
    PubMed     Text format     Abstract available


  23. POORDAD F, Felizarta F, Asatryan A, Sulkowski MS, et al
    Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment.
    Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081.
    PubMed     Text format     Abstract available


  24. BISSONNETTE J, Altamirano J, Devue C, Roux O, et al
    A Prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29080.
    PubMed     Text format     Abstract available


  25. SHIMIZU Y, Peltzer N, Sevko A, Lafont E, et al
    The linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29074.
    PubMed     Text format     Abstract available


  26. BERENGUER J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, et al
    Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29071.
    PubMed     Text format     Abstract available


  27. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Reply to "Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs".
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29069.
    PubMed     Text format    


  28. SMITH J, Rich J
    Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29070.
    PubMed     Text format    


  29. THABET K, Chan HL, Petta S, Mangia A, et al
    The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.
    Hepatology. 2017 Jan 20. doi: 10.1002/hep.29064.
    PubMed     Text format     Abstract available


  30. BOYD A, Miailhes P, Lacombe K, Zoulim F, et al
    Potential effect of lamivudine-induced S-gene mutations on liver-related pathogenesis in hepatitis D virus infection.
    Hepatology. 2017 Jan 19. doi: 10.1002/hep.29062.
    PubMed     Text format    


  31. O'BRIEN TR, Kottilil S, Feld JJ, Morgan TR, et al
    Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29057.
    PubMed     Text format    


  32. SU F, Ioannou GN
    Reply to: Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29058.
    PubMed     Text format    


  33. VERNA EC
    The Dynamic Landscape of Liver Transplant in the Era of Effective HCV Therapy.
    Hepatology. 2017 Jan 17. doi: 10.1002/hep.29054.
    PubMed     Text format    


  34. ARORA P, Basu A, Schmidt ML, Clark GJ, et al
    NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29049.
    PubMed     Text format     Abstract available


  35. HEI L, Zhong J
    LGP2 plays an essential role in HCV infection-induced interferon responses.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29050.
    PubMed     Text format     Abstract available


    December 2016
  36. SETO WK, Sau-Yan Chan T, Hwang YY, Wong DK, et al
    Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29022.
    PubMed     Text format     Abstract available


  37. LANTON T, Shriki A, Nechemia-Arbely Y, Abramovitch R, et al
    IL6-Dependent Genomic Instability Heralds Accelerated Carcinogenesis Following Liver Regeneration on a Background of Chronic Hepatitis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29004.
    PubMed     Text format     Abstract available


  38. KOWDLEY KV, Sundaram V, Jeon CY, Qureshi K, et al
    Eight weeks of Ledipasvir/Sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29005.
    PubMed     Text format     Abstract available


  39. SUN Y, Zhou J, Wang L, Wu X, et al
    New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29009.
    PubMed     Text format     Abstract available


  40. VIETHEER P, Boo I, Gu J, McCaffrey K, et al
    The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28989.
    PubMed     Text format     Abstract available


  41. BALISTRERI WF, Murray KF, Rosenthal P, Bansal S, et al
    The Safety and Effectiveness of Ledipasvir-Sofosbuvir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 1 Infection.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28995.
    PubMed     Text format     Abstract available


  42. RUBIO-TAPIA A, Hujoel IA, Smyrk TC, Poterucha JJ, et al
    Emerging secondary syphilis presenting as syphilitic hepatitis.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28974.
    PubMed     Text format    


  43. MARTINI S, Salizzoni M, David E, Tandoi F, et al
    Favorable short-term outcome of HCV-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28978.
    PubMed     Text format     Abstract available


  44. PRICE JC, Ma Y, Scherzer R, Korn N, et al
    HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28968.
    PubMed     Text format     Abstract available


  45. ARTEMOVA M, Abdurakhmanov D, Ignatova T, Mukhin N, et al
    Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy.
    Hepatology. 2016 Dec 10. doi: 10.1002/hep.28981.
    PubMed     Text format    


    November 2016
  46. KENNEDY L, Francis H
    Defining the relationship between farsenoid X receptor, hepatitis B virus X protein and HCC: It's complicated.
    Hepatology. 2016 Nov 23. doi: 10.1002/hep.28959.
    PubMed     Text format     Abstract available


  47. TSUKUDA S, Watashi K, Hojima T, Isogawa M, et al
    A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.
    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28952.
    PubMed     Text format     Abstract available


  48. LEVY PL, Duponchel S, Eischeid H, Molle J, et al
    Hepatitis C virus infection triggers a tumor-like glutamine metabolism.
    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28949.
    PubMed     Text format     Abstract available


  49. WANG L, Geng J
    Acute Hepatitis E Virus Infection in Patients with Acute Liver Failure in China: Not Quite an Uncommon Cause.
    Hepatology. 2016 Nov 10. doi: 10.1002/hep.28939.
    PubMed     Text format     Abstract available


  50. CHHATWAL J, Samur S, Kues B, Ayer T, et al
    Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28926.
    PubMed     Text format     Abstract available


  51. JOO EJ, Chang Y, Yeom JS, Ryu S, et al
    Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28917.
    PubMed     Text format     Abstract available


  52. NIU Y, Xu M, Slagle BL, Huang H, et al
    Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28924.
    PubMed     Text format     Abstract available


  53. PUNZEL M, Medd P, Hunter H, Cunningham R, et al
    Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colony-stimulating factor treatment.
    Hepatology. 2016;64:1803-1805.
    PubMed     Text format    


    October 2016
  54. QIN G, Zhuang X
    Cost-Effectiveness of Augmenting Current Perinatal Hepatitis B Prevention Program with Maternal Antiviral Therapy.
    Hepatology. 2016 Oct 27. doi: 10.1002/hep.28904.
    PubMed     Text format    


  55. SU F, Green PK, Berry K, Ioannou GN, et al
    The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28901.
    PubMed     Text format     Abstract available


  56. DAS S, Maras JS, Hussain S, Sharma S, et al
    Hyperoxidized Albumin Modulates Neutrophils to Induce Oxidative Stress and Inflammation in Severe Alcoholic Hepatitis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28897.
    PubMed     Text format     Abstract available


  57. LAWITZ E, Poordad F, Gutierrez JA, Wells JT, et al
    Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28877.
    PubMed     Text format     Abstract available


  58. WRANKE A, Calle Serrano B, Heidrich B, Kirschner J, et al
    Antiviral treatment and liver-related complications in hepatitis delta.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28876.
    PubMed     Text format     Abstract available


  59. BRADY JE, Liffmann DK, Yartel A, Kil N, et al
    Uptake of Hepatitis C Screening, Characteristics of Patients Tested, and Intervention Costs in the BEST-C Study.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28880.
    PubMed     Text format     Abstract available


  60. PIAO X, Yamazaki S, Komazawa-Sakon S, Miyake S, et al
    Depletion of myeloid cells exacerbates hepatitis and induces an aberrant increase in histone H3 in mouse serum.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28878.
    PubMed     Text format     Abstract available


  61. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  62. CHENG JY, Wong VW, Tse YK, Chim AM, et al
    Metabolic syndrome increases cardiovascular event but not hepatic event and death in patients with chronic hepatitis B.
    Hepatology. 2016 Sep 29. doi: 10.1002/hep.28778.
    PubMed     Text format     Abstract available


  63. KLEPPER A, Eng FJ, Doyle EH, El-Shamy A, et al
    Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28846.
    PubMed     Text format     Abstract available


  64. WANG RY, Bare P, De Giorgi V, Matsuura K, et al
    Preferential Association of Hepatitis C Virus with CD19+ B Cells Is Mediated by Complement System.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28842.
    PubMed     Text format     Abstract available


  65. KECK ZY, Wang Y, Lau P, Lund G, et al
    Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28850.
    PubMed     Text format     Abstract available


  66. ROSEN HR
    "Hep C, where art thou": What are the remaining (fundable) questions in HCV research?
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28848.
    PubMed     Text format    


  67. NISHIO A, Tatsumi T, Nawa T, Suda T, et al
    CD14+ monocyte-derived Galectin-9 induces NK cell cytotoxicity in chronic hepatitis C.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28847.
    PubMed     Text format     Abstract available


  68. MITRA B, Guo H
    Hepatitis B Virus X Protein Crosses Out Smc5/6 Complex to Maintain cccDNA Transcription.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28834.
    PubMed     Text format    


  69. MARTINELLO M, Gane E, Hellard M, Sasadeusz J, et al
    Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28844.
    PubMed     Text format     Abstract available


  70. XIANG M, Liu T, Tan W, Ren H, et al
    Effects of kinsenoside, a potential immunosuppressive drug for autoimmune hepatitis, on DCs-CD8+ T cells communication.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28825.
    PubMed     Text format     Abstract available


  71. HILL LA, Wyles DL
    Emerging complexities with HCV DAA regimens: Less is still way more.
    Hepatology. 2016 Sep 16. doi: 10.1002/hep.28832.
    PubMed     Text format    


  72. BROWN A, Halliday JS, Swadling L, Madden R, et al
    Characterisation of the specificity, functionality and durability of host T-cell responses against the full-length hepatitis E virus.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28819.
    PubMed     Text format     Abstract available


  73. RENOU C, Lesgourgues B, Macaigne G, Pauwels A, et al
    Hepatitis E in decompensated alcoholic cirrhosis.
    Hepatology. 2016 Sep 12. doi: 10.1002/hep.28792.
    PubMed     Text format    


    August 2016
  74. WELLER R, Todt D, Engelmann M, Friesland M, et al
    Apolipoprotein E polymorphisms and their protective effect on Hepatitis E virus replication.
    Hepatology. 2016 Aug 19. doi: 10.1002/hep.28788.
    PubMed     Text format    


  75. TEO CG, Yesupriya A, Chang MH, Zhang L, et al
    "Apolipoprotein E polymorphisms and their protective effect on Hepatitis E virus replication" by Weller et al.
    Hepatology. 2016 Aug 19. doi: 10.1002/hep.28787.
    PubMed     Text format    


  76. DORE GJ
    Hepatitis C Treatment as Prevention among HIV-infected Men who have Sex with Men: Feasible?
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28784.
    PubMed     Text format    


  77. SALAZAR-VIZCAYA L, Kouyos RD, Zahnd C, Wandeler G, et al
    Hepatitis C virus transmission among HIV-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28769.
    PubMed     Text format     Abstract available


  78. TAWAR RG, Heydmann L, Bach C, Schuttrumpf J, et al
    Broad neutralization of hepatitis C virus resistant variants by Civacir(R) hepatitis C immune globulin.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28767.
    PubMed     Text format     Abstract available


  79. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Text format     Abstract available


  80. LE GAL F, Brichler S, Sahli R, Chevret S, et al
    First International External Quality Assessment for Hepatitis Delta Virus RNA Quantification in Plasma.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28772.
    PubMed     Text format     Abstract available


  81. BANKWITZ D, Pietschmann T
    Hepatitis C virus plays hide and seek with neutralizing antibodies.
    Hepatology. 2016 Aug 12. doi: 10.1002/hep.28760.
    PubMed     Text format    


  82. SAYED IM, Vercouter AS, Meuleman P
    Hepatitis E virus in acute liver failure: An unusual suspect?
    Hepatology. 2016 Aug 6. doi: 10.1002/hep.28759.
    PubMed     Text format    


  83. PAWLOTSKY JM
    The end of the hepatitis C burden: Really?
    Hepatology. 2016 Aug 3. doi: 10.1002/hep.28758.
    PubMed     Text format    


  84. GRAGNANI L, Visentini M, Fognani E, Urraro T, et al
    Prospective Study of Guideline-Tailored Therapy with Direct-Acting Antivirals for Hepatitis C Virus-Associated Mixed Cryoglobulinemia.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28753.
    PubMed     Text format     Abstract available


  85. ABE-CHAYAMA H, Hayes CN, Chayama K
    Pan-genotypic cell culture system for propagation of hepatitis c virus clinical isolates.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28751.
    PubMed     Text format    


  86. BRAHM J, Castera L, Hou J, Lindor K, et al
    Joint society statement for the elimination of viral hepatitis.
    Hepatology. 2016 Aug 1. doi: 10.1002/hep.28730.
    PubMed     Text format    


    July 2016
  87. REGAN CP, Morissette P, Regan HK, Travis JJ, et al
    Preclinical Assessment of the Clinical Cardiac Drug-Drug Interaction Associated with the Combination of HCV-NI Antivirals and Amiodarone.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28752.
    PubMed     Text format     Abstract available


  88. DUSHEIKO G, Easterbrook P
    Bringing to an end mother to child transmission of hepatitis B: A role for quantitative HBsAg?
    Hepatology. 2016 Jul 25. doi: 10.1002/hep.28732.
    PubMed     Text format    


  89. SUGIYAMA M, Kanto T
    Dual blockade of HCV entry at a gatekeeper of hepatocytes - Not only a preventive but also therapeutic target of CLDN-1.
    Hepatology. 2016 Jul 12. doi: 10.1002/hep.28726.
    PubMed     Text format    



  90. Correction: A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.
    Hepatology. 2016;64:324.
    PubMed     Text format    


    June 2016
  91. ABERGEL A, Metivier S, Samuel D, Jiang D, et al
    Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28706.
    PubMed     Text format     Abstract available


  92. PRENTOE J, Velazquez-Moctezuma R, Foung SK, Law M, et al
    Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28705.
    PubMed     Text format     Abstract available


  93. GANNE-CARRIE N, Layese R, Bourcier V, Cagnot C, et al
    Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702.
    PubMed     Text format     Abstract available


  94. SPENGLER EK, Kleiner DE, Fontana RJ
    Vemurafenib-induced Granulomatous hepatitis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28692.
    PubMed     Text format    


  95. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Text format     Abstract available


  96. ZHANG H, Xing Z, Mani SK, Bancel B, et al
    RNA helicase DDX5 regulates PRC2/HOTAIR function in Hepatitis B Virus infection and hepatocarcinogenesis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28698.
    PubMed     Text format     Abstract available


  97. THOMSEN MK, Nandakumar R, Stadler D, Malo A, et al
    Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection.
    Hepatology. 2016 Jun 16. doi: 10.1002/hep.28685.
    PubMed     Text format     Abstract available


  98. HUANG F, Li Y, Yu W, Jing S, et al
    Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis.
    Hepatology. 2016 Jun 10. doi: 10.1002/hep.28668.
    PubMed     Text format     Abstract available


  99. HU KQ, Cui W
    A Highly Specific and Sensitive Hepatitis C Virus Antigens Enzyme Immunoassay for One-step Diagnosis of Viremic HCV Infection.
    Hepatology. 2016 Jun 6. doi: 10.1002/hep.28663.
    PubMed     Text format     Abstract available


    May 2016
  100. SUNG FY, Lan CY, Huang CJ, Lin CL, et al
    Progressive accumulation of mutations in the hepatitis B virus genome and its impact for time to diagnosis of hepatocellular carcinoma.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28654.
    PubMed     Text format     Abstract available


  101. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Text format     Abstract available


  102. FONTANA RJ, Engle RE, Scaglione S, Araya V, et al
    The role of hepatitis E virus infection in Adult Americans with acute liver failure.
    Hepatology. 2016 May 23. doi: 10.1002/hep.28649.
    PubMed     Text format     Abstract available


  103. NATHANSON MH, Terrault N
    Hepatitis B surface antigen loss: Not all that we hoped it would be.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28640.
    PubMed     Text format    


  104. SCHREIBER J, McNally J, Chodavarapu K, Svarovskaia E, et al
    Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28636.
    PubMed     Text format    


  105. TOYODA H, Kumada T, Tada T
    Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.
    Hepatology. 2016 May 2. doi: 10.1002/hep.28632.
    PubMed     Text format    


  106. PAPATHEODORIDIS G, Vlachogiannakos I, Cholongitas E, Wursthorn K, et al
    Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.
    Hepatology. 2016;63:1481-1492.
    PubMed     Text format     Abstract available


  107. SCHLEGEL M, Kohler D, Korner A, Granja T, et al
    The neuroimmune guidance cue netrin-1 controls resolution programs and promotes liver regeneration.
    Hepatology. 2016;63:1689-705.
    PubMed     Text format     Abstract available


    April 2016
  108. FUJITA T
    Assessing endotoxemia in alcoholic hepatitis.
    Hepatology. 2016 Apr 28. doi: 10.1002/hep.28629.
    PubMed     Text format    


  109. ASIMAKOPOULOS A, Mangia A, Dore GJ, Lloyd AR, et al
    Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans.
    Hepatology. 2016 Apr 27. doi: 10.1002/hep.28626.
    PubMed     Text format    


  110. ZHOU YH
    Prevention of Mother-to-Child Transmission of Hepatitis B Virus by Treating Mothers with High Viral Loads.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28619.
    PubMed     Text format    


  111. HALFON P, Mohamed S, Penaranda G, Khiri H, et al
    Hepatitis c genotype 4r resistance associated polymorphisms: The achilles heel of the NS5A inhibitors?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28611.
    PubMed     Text format    


  112. VERLINDEN W, Francque S, Michielsen P, Vanwolleghem T, et al
    Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28610.
    PubMed     Text format    


  113. FOSCHI A, Casana M, Radice A, Ranieri R, et al
    CORRESPONDENCE: Hepatitis C management in prisons: An insight into daily clinical practice in three major Italian Correctional Houses.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28609.
    PubMed     Text format    


  114. BACKUS LI, Belperio PS, Shahoumian TA, Loomis TP, et al
    Real World Effectiveness of Ledipasvir/Sofosbuvir in 4365 Treatment-Naive Genotype 1 Hepatitis C Infected Patients.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28625.
    PubMed     Text format     Abstract available


  115. MARTIN NK, Vickerman P, Hickman M
    CORRESPONDENCE: HCV testing and treatment in Italian prisons: Implications for prevention benefit and cost-effectiveness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28612.
    PubMed     Text format    


  116. LIU J, Yang HI, Lee MH, Jen CL, et al
    Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28552.
    PubMed     Text format     Abstract available


  117. WEN WH, Huang CW, Chie WC, Yeung CY, et al
    Quantitative Maternal Hepatitis B Surface Antigen Predicts Maternally Transmitted Hepatitis B Virus Infection.
    Hepatology. 2016 Apr 4. doi: 10.1002/hep.28589.
    PubMed     Text format     Abstract available


  118. OZARAS R, Sunbul M, Parlak M, Bodur H, et al
    Treating HBV/HCV Co-infected Patients with Direct Acting HCV Antivirals Only is not Safe.
    Hepatology. 2016 Apr 4. doi: 10.1002/hep.28592.
    PubMed     Text format    


  119. MANSUY JM, Gallian P, Dimeglio C, Saune K, et al
    A nationwide survey of hepatitis E viral infection in French blood donors.
    Hepatology. 2016;63:1145-54.
    PubMed     Text format     Abstract available


  120. LI KK, Trivedi PJ, Von Heimendahl S, Bruns T, et al
    Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?
    Hepatology. 2016;63:1394-5.
    PubMed     Text format    


  121. CUBERO FJ
    Shutting off inflammation: A novel switch on hepatic stellate cells.
    Hepatology. 2016;63:1086-9.
    PubMed     Text format    


  122. BARTNECK M, Fech V, Ehling J, Govaere O, et al
    Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.
    Hepatology. 2016;63:1310-24.
    PubMed     Text format     Abstract available


    March 2016
  123. KUNIHOLM MH, Nelson KE
    Reply: Acute and Chronic Hepatitis E Virus Infection in HIV-Infected U.S. Women.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28581.
    PubMed     Text format    


  124. PONZETTO A, Carloni G
    HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28580.
    PubMed     Text format    


  125. SU TH, Chen CL, Kao JH
    RE: HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28578.
    PubMed     Text format    


  126. SPACEK LA
    Comment on: Acute and Chronic Hepatitis E Virus Infection in Human Immunodeficiency Virus-Infected U.S. Women.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28582.
    PubMed     Text format    


  127. CHHATWAL J, Wang X, Ayer T, Kabiri M, et al
    Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28571.
    PubMed     Text format     Abstract available


  128. VARGAS H
    Hepatitis C Treatment In 2016: Reasons to be an OPTIMIST.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28559.
    PubMed     Text format    


  129. WROBLEWSKI R, Armaka M, Kondylis V, Pasparakis M, et al
    Opposing Role of Tumor Necrosis Factor Receptor 1 Signaling in T Cell Mediated Hepatitis and Bacterial Infection In Mice.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28551.
    PubMed     Text format     Abstract available


  130. BUTI M, Sanchez-Ruano J, Morillas RM, Esteban R, et al
    Baseline HCV-RNA levels in genotype 1 Chronic Hepatitis C Patients: The role of different cut-off points.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28544.
    PubMed     Text format    


  131. PEIFFER KH, Sommer L, Zeuzem S, Sarrazin C, et al
    Reply to the letter to the editor "Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a".
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28536.
    PubMed     Text format    


  132. EL-SERAG HB, Kanwal F, Richardson P, Kramer J, et al
    Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28535.
    PubMed     Text format     Abstract available


  133. PEDERGNANA V, Smith D, Klenerman P, Barnes E, et al
    Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28533.
    PubMed     Text format    


  134. MANDREKAR P, Bataller R, Tsukamoto H, Gao B, et al
    Alcoholic hepatitis: Translational approaches to develop targeted therapies.
    Hepatology. 2016 Mar 3. doi: 10.1002/hep.28530.
    PubMed     Text format     Abstract available



  135. Correction: Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma.
    Hepatology. 2016;63:1064.
    PubMed     Text format    


  136. DANDRI M, Bockmann JH
    The challenge of protecting without overprotecting: The two sides of myeloid-derived suppressor cells in hepatitis B viral infection.
    Hepatology. 2016;63:1043-6.
    PubMed     Text format    


  137. HOFFMANN F, Endres S, Rothenfusser S
    Reply.
    Hepatology. 2016;63:1062-3.
    PubMed     Text format    


    February 2016
  138. SIMON TG, Bonilla H, Yan P, Chung RT, et al
    Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV Results from ERCHIVES.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28506.
    PubMed     Text format     Abstract available


  139. TANG DM, Heller T, Koh C
    The many faces of positive hepatitis B surface antigen.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28503.
    PubMed     Text format    


  140. MELLINGER J, Fontana RJ
    Quality of care metrics in chronic hepatitis B.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28500.
    PubMed     Text format    


  141. SCHNABL B
    Liver Capsule: Mechanisms Of Alcoholic Hepatitis.
    Hepatology. 2016 Feb 11. doi: 10.1002/hep.28488.
    PubMed     Text format    


  142. MARTIN NK, Vickerman P, Brew IF, Williamson J, et al
    Is increased HCV case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis.
    Hepatology. 2016 Feb 10. doi: 10.1002/hep.28497.
    PubMed     Text format     Abstract available


  143. LINDENBACH BD
    "What's next for hepatitis C virus research?"
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28494.
    PubMed     Text format    


  144. HEZODE C, Chevaliez S, Scoazec G, Soulier A, et al
    Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen.
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28491.
    PubMed     Text format     Abstract available


  145. HADZIC N, Bansal S
    Hepatitis B virus in children: More therapeutic options-but unknown and known unknowns still present.
    Hepatology. 2016;63:360-2.
    PubMed     Text format    


    January 2016
  146. LEROY V, Angus P, Bronowicki JP, Dore GJ, et al
    Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+).
    Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473.
    PubMed     Text format     Abstract available


  147. SACK J, Garcia-Tsao G
    Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28470.
    PubMed     Text format    


  148. KWO P, Gitlin N, Nahass R, Bernstein D, et al
    Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467.
    PubMed     Text format     Abstract available


  149. WONG TC, Lan A, Kiser J, Anderson PL, et al
    Novel Quantification of TDF adherence in HIV-hepatitis B co-infected patients with incomplete HBV viral suppression.
    Hepatology. 2016 Jan 21. doi: 10.1002/hep.28461.
    PubMed     Text format    


  150. BOYD A, Peytavin G, Lacombe K
    Reply to: Novel Quantification of TDF adherence in HIV-hepatitis B co-infected patients with incomplete HBV viral suppression.
    Hepatology. 2016 Jan 19. doi: 10.1002/hep.28463.
    PubMed     Text format    


  151. ZHANG ZF, Duan ZJ
    A methodology concern of the meta-analysis of antiviral therapy for chronic hepatitis B virus infection in adults.
    Hepatology. 2016 Jan 16. doi: 10.1002/hep.28455.
    PubMed     Text format    


  152. INNES H, Hutchinson SJ, Obel N, Christensen PB, et al
    Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland - using spontaneous resolvers as the benchmark comparator.
    Hepatology. 2016 Jan 16. doi: 10.1002/hep.28458.
    PubMed     Text format     Abstract available


  153. DAHARI H, Cotler SJ, Feld JJ
    Cure prevents more than transmission of HCV.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28449.
    PubMed     Text format    


  154. POORDAD F, Schiff ER, Vierling JM, Landis C, et al
    Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446.
    PubMed     Text format     Abstract available


  155. SUNAMI Y, Ringelhan M, Kokai E, Lu M, et al
    Canonical NF-kappaB signaling in hepatocytes acts as a tumor-suppressor in HBV surface antigen-driven HCC by controlling the UPR.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28435.
    PubMed     Text format     Abstract available



  156. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.
    Hepatology. 2016;63:349.
    PubMed     Text format    


  157. MERRIMAN RB, Tran TT
    AASLD practice guidelines: The past, the present, and the future.
    Hepatology. 2016;63:31-4.
    PubMed     Text format    


    December 2015
  158. DESOMBERE I, Fafi-Kremer S, Van Houtte F, Pessaux P, et al
    Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28428.
    PubMed     Text format     Abstract available


  159. REIN DB, Borton J, Liffmann DK, Wittenborn JS, et al
    The burden of hepatitis C to the United States medicare system in 2009: Descriptive and economic characteristics.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28430.
    PubMed     Text format     Abstract available


  160. SAAB S, Park SH, Mizokami M, Omata M, et al
    Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28425.
    PubMed     Text format     Abstract available


  161. JIANG DK, Wu X, Qian J, Ma XP, et al
    Genetic variation in STAT4 predicts response to interferon-alpha therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28423.
    PubMed     Text format     Abstract available


  162. LAWITZ E, Matusow G, DeJesus E, Yoshida EM, et al
    Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422.
    PubMed     Text format     Abstract available


  163. GALMOZZI E
    Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28421.
    PubMed     Text format    


  164. BELAND K, Alvarez F
    Anti-CD20 monoclonal antibody for the treatment of patients with autoimmune hepatitis.
    Hepatology. 2015 Dec 17. doi: 10.1002/hep.28407.
    PubMed     Text format    


  165. SIRA MM, Sira AM
    B cell depletion in autoimmune hepatitis: Is it safe for the bowel?
    Hepatology. 2015 Dec 17. doi: 10.1002/hep.28405.
    PubMed     Text format    


  166. MEHTA N, Yao FY
    Nucleos(t)ide analogues to reduce the risk of Hepatitis B associated hepatocellular carcinoma: A can't miss proposition?
    Hepatology. 2015 Dec 17. doi: 10.1002/hep.28404.
    PubMed     Text format    


  167. LIN J, Ou HY, Chuang LM, Chiu KC, et al
    Diabetes prevention through prevention of hepatitis B.
    Hepatology. 2015 Dec 13. doi: 10.1002/hep.28399.
    PubMed     Text format    


  168. WIELAND D, Thimme R
    Vaccine-induced HCV-specific CD8+ T cells do not always help.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28388.
    PubMed     Text format    


  169. SU TH, Liu CJ, Tseng TC, Chou SW, et al
    Hepatitis C virus infection increases the risk of lymphoid-neoplasms: A population-based cohort study.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28387.
    PubMed     Text format     Abstract available


  170. CHEN DS, Liaw YF, Chen CJ, Wu JC, et al
    Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28378.
    PubMed     Text format    


  171. KUNIHOLM MH, Ong E, Hogema BM, Koppelman M, et al
    Acute and Chronic Hepatitis E Virus Infection in HIV-Infected United States Women.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28384.
    PubMed     Text format     Abstract available


  172. JARUVONGVANICH V, Upala S, Sanguankeo A
    Association between systemic inflammatory response syndrome and mortality in alcoholic hepatitis: A meta-analysis.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28366.
    PubMed     Text format    


  173. SPRADLING PR, Bulkow LR, Negus SE, Homan C, et al
    Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.
    Hepatology. 2015 Dec 5. doi: 10.1002/hep.28375.
    PubMed     Text format     Abstract available


    November 2015
  174. PISCAGLIA F, Svegliati-Baroni G, Barchetti A, Pecorelli A, et al
    Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368.
    PubMed     Text format     Abstract available


  175. LOK AS, McMahon BJ, Brown RS Jr, Wong JB, et al
    Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28280.
    PubMed     Text format     Abstract available


  176. JONAS MM, Lok AS, McMahon BJ, Brown RS Jr, et al
    Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28278.
    PubMed     Text format     Abstract available


  177. TERRAULT NA, Bzowej NH, Chang KM, Hwang JP, et al
    AASLD guidelines for treatment of chronic hepatitis B.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28156.
    PubMed     Text format    


  178. BROWN RS JR, McMahon BJ, Lok AS, Wong JB, et al
    Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28302.
    PubMed     Text format     Abstract available


  179. GALUN E
    Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor-promoting niche (TPN) in the development of hepatocellular carcinoma.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28344.
    PubMed     Text format    


  180. SERPER M, Choi G, Forde KA, Kaplan DE, et al
    Care delivery and outcomes among U.S. veterans with hepatitis B: A national cohort study.
    Hepatology. 2015 Nov 11. doi: 10.1002/hep.28340.
    PubMed     Text format     Abstract available


  181. WILDER JM, Jeffers LJ, Ravendhran N, Shiffman ML, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data.
    Hepatology. 2015 Nov 6. doi: 10.1002/hep.28334.
    PubMed     Text format     Abstract available


  182. HOPCRAFT SE, Evans MJ
    Liver Capsule: HCV Host Cell Entry.
    Hepatology. 2015 Nov 4. doi: 10.1002/hep.28329.
    PubMed     Text format    


  183. CHIDI AP, Rogal S, Bryce CL, Fine MJ, et al
    Cost-Effectiveness of New Antiviral Regimens for Treatment-Naive US Veterans with Hepatitis C.
    Hepatology. 2015 Nov 2. doi: 10.1002/hep.28327.
    PubMed     Text format     Abstract available


  184. JUNG M, Kuniholm MH, Ho GY, Cotler S, et al
    The distribution of Hepatitis B virus exposure and infection in a population-based sample of US Hispanic adults.
    Hepatology. 2015 Nov 2. doi: 10.1002/hep.28328.
    PubMed     Text format     Abstract available


  185. CABALLERIA J
    Reply: To PMID 25502967.
    Hepatology. 2015;62:1644.
    PubMed     Text format    


  186. DITAH I, Charlton M
    Genetic susceptibility to hepatitis E viral infection: An enigmatic virus gives up a secret.
    Hepatology. 2015;62:1337-8.
    PubMed     Text format    


    October 2015
  187. BURZA MA, Motta BM, Mancina RM, Pingitore P, et al
    DEPDC5 variants increase fibrosis progression in Europeans with chronic HCV infection.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28322.
    PubMed     Text format     Abstract available


  188. CALLENDRET B, Eccleston HB, Satterfield W, Capone S, et al
    Persistent HCV replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and direct acting antiviral.
    Hepatology. 2015 Oct 29. doi: 10.1002/hep.28309.
    PubMed     Text format     Abstract available


  189. FAN L, Owusu-Edusei K, Schillie SF, Murphy TV, et al
    Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection.
    Hepatology. 2015 Oct 28. doi: 10.1002/hep.28310.
    PubMed     Text format     Abstract available


  190. URBAN S
    Entry and entry inhibition of Hepatitis B (HBV) and Hepatitis Delta Virus (HDV) into hepatocytes.
    Hepatology. 2015 Oct 26. doi: 10.1002/hep.28308.
    PubMed     Text format    


  191. BRETT-MAJOR DM, Frick KD, Malia JA, Hakre S, et al
    Costs and consequences: Hepatitis C seroprevalance in the military and its impact on potential screening strategies.
    Hepatology. 2015 Oct 20. doi: 10.1002/hep.28303.
    PubMed     Text format     Abstract available


  192. BELAND K, Alvarez F
    Role(s) of b cells in autoimmune hepatitis pathogenesis.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28299.
    PubMed     Text format    


  193. DONG JZ, Wang LP, Zhu JH
    B cells in autoimmune hepatitis: Friend or foe?
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28298.
    PubMed     Text format    


  194. SISE ME, Bloom AK, Wisocky J, Lin MV, et al
    Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with Sofosbuvir-Based Direct-Acting Antiviral Agents.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28297.
    PubMed     Text format     Abstract available


  195. KELLY C, Swadling L, Capone S, Brown A, et al
    Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28294.
    PubMed     Text format     Abstract available


  196. O'BRIEN TR, Feld JJ, Kottilil S, Pfeiffer RM, et al
    No Scientific Basis to Restrict 8 Weeks of Treatment with Ledipasvir/Sofosbuvir to Patients with HCV RNA <6,000,000 IU/ml.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28292.
    PubMed     Text format    


  197. YOSHIO S, Sugiyama M, Shoji H, Mano Y, et al
    Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.
    Hepatology. 2015 Oct 12. doi: 10.1002/hep.28282.
    PubMed     Text format     Abstract available


  198. PUBLICOVER J, Jespersen JM, Johnson AJ, Nishimura SL, et al
    Age-influenced hepatic immune priming determines HBV infection fate; implications from Mouse to Man.
    Hepatology. 2015 Oct 12. doi: 10.1002/hep.28284.
    PubMed     Text format    


  199. NJEI B, Do A, Lim JK
    Prevalence of Hepatitis Delta Infection in the United States: NHANES 1999-2012.
    Hepatology. 2015 Oct 9. doi: 10.1002/hep.28279.
    PubMed     Text format    


  200. LEE TY, Lin JT, Zeng YS, Chen YJ, et al
    Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation.
    Hepatology. 2015 Oct 1. doi: 10.1002/hep.28266.
    PubMed     Text format     Abstract available


    September 2015
  201. COLSON P, Borentain P, Dhiver C, Benhaim S, et al
    Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France.
    Hepatology. 2015 Sep 29. doi: 10.1002/hep.28261.
    PubMed     Text format    


  202. PEIFFER KH, Sommer L, Susser S, Vermehren J, et al
    IFN lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients.
    Hepatology. 2015 Sep 25. doi: 10.1002/hep.28255.
    PubMed     Text format     Abstract available


  203. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28227.
    PubMed     Text format     Abstract available


  204. PRIGOZHIN DM, Modis Y
    Flunarizine Arrests Hepatitis C Virus Membrane Fusion.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28224.
    PubMed     Text format    


  205. WU JF, Chiu YC, Chang KC, Chen HL, et al
    Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus infected patients from childhood to adulthood.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28222.
    PubMed     Text format     Abstract available


  206. BONI C, Lampertico P, Talamona L, Giuberti T, et al
    NK cell phenotype modulation and NK/T cell interplay in nucleos(t)ide analogue treated HBeAg- patients with chronic hepatitis B.
    Hepatology. 2015 Sep 11. doi: 10.1002/hep.28155.
    PubMed     Text format     Abstract available


  207. CHUNG RT, Pearson S, Hur C
    Tackling the Hepatitis C Cost Problem: A Test Case for Tomorrow's Cures.
    Hepatology. 2015 Sep 11. doi: 10.1002/hep.28157.
    PubMed     Text format    


  208. ZOULIM F, Testoni B
    Validated and Potential Novel Targets to Treat Hepatitis B Virus.
    Hepatology. 2015 Sep 4. doi: 10.1002/hep.28144.
    PubMed     Text format    


    August 2015
  209. SEHGAL R, Patra S, David P, Vyas A, et al
    Impaired monocyte - macrophage functions and defective tlr signalling in hepatitis e virus infected pregnant women with acute liver failure.
    Hepatology. 2015 Aug 31. doi: 10.1002/hep.28143.
    PubMed     Text format     Abstract available


  210. SORIANO V, Barreiro P, de Mendoza C
    Hypoglycemia in a diabetic patient during hepatitis C therapy.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28137.
    PubMed     Text format    


  211. SIMON TG, Chung RT
    HEP-15-1079: The new HCV bottleneck: can delaying therapy be justified Reply to Letter to the Editor (LTE).
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28136.
    PubMed     Text format    


  212. LI J, Wands J
    Hepatitis B and D Viral Receptors.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28131.
    PubMed     Text format    


  213. WINER BY, Ploss A
    Breaking the species barrier for hepatitis delta virus.
    Hepatology. 2015 Aug 20. doi: 10.1002/hep.28129.
    PubMed     Text format    


  214. CHIRIKOV VV, Shaya F, Mullins CD, dosReis S, et al
    Research is needed on the difficult-to-cure population of HCV patients with disability.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28120.
    PubMed     Text format    


  215. KHALILI M, Lombardero M, Chung RT, Terrault NA, et al
    Diabetes and Prediabetes in Patients with Hepatitis B Residing in North America.
    Hepatology. 2015 Aug 8. doi: 10.1002/hep.28110.
    PubMed     Text format     Abstract available


  216. WONG DK
    Hepatoma in hepatitis B - Infectious disease or Liver disease?
    Hepatology. 2015 Aug 7. doi: 10.1002/hep.28118.
    PubMed     Text format    


  217. ROBERTS H, Kruszon-Moran D, Ly KN, Hughes E, et al
    Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households - national health and nutrition examination survey (NHANES), 1988-2012.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28109.
    PubMed     Text format     Abstract available


  218. KACHKO A, Frey SE, Sirota L, Ray R, et al
    Antibodies to an interfering epitope in hepatitis C Virus E2 can mask vaccine-induced neutralizing activity.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28108.
    PubMed     Text format     Abstract available


  219. WANG H, El Maadidi S, Fischer J, Grabski E, et al
    A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28105.
    PubMed     Text format     Abstract available


  220. TURNER B, Taylor B, Hanson J, Liang Y, et al
    High Priority for Hepatitis C Screening in Safety Net Hospitals: Results from a Prospective Cohort of 4582 Hospitalized Baby Boomers.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28018.
    PubMed     Text format     Abstract available


  221. JUNG KS, Kim SU, Song K, Park JY, et al
    Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28115.
    PubMed     Text format     Abstract available


  222. FUJII Y, Uchida Y, Mochida S
    Reply to the Letter Entitled "Severe Hepatotoxicity Associated with Asunaprevir and Daclatasvir in Chronic Hepatitis C".
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28114.
    PubMed     Text format    


  223. SHIBATA S, Umemura T, Komatsu M, Tanaka E, et al
    Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis C.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28113.
    PubMed     Text format    


  224. FUJITA T, Soontrapa K, Ito Y, Iwaisako K, et al
    Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immune-mediated hepatitis.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28112.
    PubMed     Text format     Abstract available


  225. PERIN PM, Haid S, Brown RJ, Doerrbecker J, et al
    Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28111.
    PubMed     Text format     Abstract available


  226. RICE C, Chen Z
    Repurposing an old drug: A low-cost allergy medication provides new hope for hepatitis C patients.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28028.
    PubMed     Text format    


  227. GISH RG, Cohen CA, Block JM, Brosgart CL, et al
    Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28026.
    PubMed     Text format    


  228. LIANG TJ, Block TM, McMahon BJ, Ghany MG, et al
    Present and future therapies of hepatitis B: From discovery to cure.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28025.
    PubMed     Text format     Abstract available


  229. KANNINEN TT, Dieterich D, Asciutti S
    HCV vertical transmission in pregnancy: New horizons in the era of DAAs.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28032.
    PubMed     Text format     Abstract available


  230. WENZEL JJ, Jilg W
    Reply: To PMID 24912687.
    Hepatology. 2015;62:654.
    PubMed     Text format    


    July 2015
  231. VERRIER ER, Colpitts CC, Bach C, Heydmann L, et al
    A targeted functional RNAi screen uncovers Glypican 5 as an entry factor for hepatitis B and D viruses.
    Hepatology. 2015 Jul 29. doi: 10.1002/hep.28013.
    PubMed     Text format     Abstract available


  232. JONAS MM, Chang MH, Sokal E, Schwarz KB, et al
    Randomized Controlled Trial of Entecavir Versus Placebo in Children with HBeAg-positive Chronic Hepatitis B.
    Hepatology. 2015 Jul 29. doi: 10.1002/hep.28015.
    PubMed     Text format     Abstract available


  233. LIU X, Jiang X, Liu R, Wang L, et al
    B cells expressing CD11b effectively inhibit CD4 T cell responses and ameliorate experimental autoimmune hepatitis.
    Hepatology. 2015 Jul 24. doi: 10.1002/hep.28001.
    PubMed     Text format     Abstract available


  234. YUKSEL M, Wang Y, Tai N, Peng J, et al
    A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation.
    Hepatology. 2015 Jul 16. doi: 10.1002/hep.27998.
    PubMed     Text format     Abstract available


  235. KIRSTEIN MM, Metzler F, Geiger E, Heinrich E, et al
    Prediction of short- and long-term outcome in patients with autoimmune hepatitis.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27983.
    PubMed     Text format     Abstract available


  236. BELAND K, Marceau G, Labardy A, Bourbonnais S, et al
    Depletion of B cells induce remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27991.
    PubMed     Text format     Abstract available


  237. EDLIN BR, Eckhardt BJ, Shu MA, Holmberg SD, et al
    Towards a more accurate estimate of the prevalence of hepatitis C in the United States.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27978.
    PubMed     Text format     Abstract available


  238. KUMADA H, Chayama K, Rodrigues-Jr L, Suzuki F, et al
    Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir for HCV Genotype 1b-infected Japanese Patients With or Without Cirrhosis.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27972.
    PubMed     Text format     Abstract available


  239. CARLIN AF, Aristizabal P, Song Q, Wang H, et al
    Temporal dynamics of inflammatory cytokines/chemokines during Sofosbuvir and Ribavirin therapy for Genotype 2 and 3 Hepatitis C infection.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27971.
    PubMed     Text format     Abstract available


  240. DE MARTEL C, Maucort-Boulch D, Plummer M, Franceschi S, et al
    Worldwide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27969.
    PubMed     Text format     Abstract available


  241. COOMBES JD, Syn WK
    Differential osteopontin functions: The role of osteopontin isoforms.
    Hepatology. 2015;62:323-4.
    PubMed     Text format    


  242. LAZARO R, Wu R, Tsukamoto H
    Reply.
    Hepatology. 2015;62:324.
    PubMed     Text format    


  243. PERRILLO RP
    Tumor necrosis factor inhibitor therapy for hepatitis B virus-infected individuals: How loud is the alarm bell?
    Hepatology. 2015;62:16-8.
    PubMed     Text format    


  244. VANWOLLEGHEM T, Hou J, van Oord G, Andeweg AC, et al
    Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells.
    Hepatology. 2015;62:87-100.
    PubMed     Text format     Abstract available


  245. BARONE M, Notarnicola A, Lopalco G, Viggiani MT, et al
    Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection.
    Hepatology. 2015;62:40-6.
    PubMed     Text format     Abstract available


    June 2015
  246. CHAPKO MK, Dufour DR, Hatia R, Drobeniuc J, et al
    Cost-effectiveness of strategies for testing current hepatitis C virus infection.
    Hepatology. 2015 Jun 30. doi: 10.1002/hep.27966.
    PubMed     Text format     Abstract available


  247. TAKAMATSU Y, Tanaka Y, Kohgo S, Murakami S, et al
    4'-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus.
    Hepatology. 2015 Jun 29. doi: 10.1002/hep.27962.
    PubMed     Text format     Abstract available


  248. PAWLOTSKY JM, Flisiak R, Sarin SK, Rasenack J, et al
    Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection.
    Hepatology. 2015 Jun 27. doi: 10.1002/hep.27960.
    PubMed     Text format     Abstract available



  249. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27950.
    PubMed     Text format    


  250. LI M, Mennone A, Soroka CJ, Hagey LR, et al
    NHERF-1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27956.
    PubMed     Text format     Abstract available


  251. VERGARA C, Thio CL, Thomas D, Duggal P, et al
    Polymorphisms In Melanoma Differentiation-Associated Gene 5 Are Not Associated With Clearance Of Hepatitis C Virus In A European American Population.
    Hepatology. 2015 Jun 23. doi: 10.1002/hep.27954.
    PubMed     Text format    


  252. PEDERGNANA V, Abdel-Hamid M, Guergnon J, Theodorou I, et al
    Refined association of MDA5 variants with spontaneous hepatitis C virus clearance in Egypt.
    Hepatology. 2015 Jun 23. doi: 10.1002/hep.27951.
    PubMed     Text format    


  253. SHLOMAI A
    Hepatitis C virus addiction to liver miR-122 takes its toll on the host.
    Hepatology. 2015 Jun 19. doi: 10.1002/hep.27947.
    PubMed     Text format    


  254. SORIANO V, Barreiro P, de Mendoza C
    Tenofovir for hepatitis delta.
    Hepatology. 2015 Jun 19. doi: 10.1002/hep.27946.
    PubMed     Text format    


  255. ZHANG L, Yesupriya A, Chang MH, Teshale E, et al
    Apolipoprotein E and protection against hepatitis E virus infection in American, non-Hispanic blacks.
    Hepatology. 2015 Jun 11. doi: 10.1002/hep.27938.
    PubMed     Text format     Abstract available


  256. AQEL B, Pungpapong S, Leise M, Werner KT, et al
    Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology. 2015 Jun 11. doi: 10.1002/hep.27937.
    PubMed     Text format     Abstract available


  257. VERRIER ER, Wieland S, Baumert TF
    RIG-I and sensing of hepatitis B virus revisited.
    Hepatology. 2015 Jun 10. doi: 10.1002/hep.27935.
    PubMed     Text format    


  258. LONTOK E, Harrington P, Howe A, Kieffer T, et al
    Hepatitis C Virus Drug Resistance-associated Substitutions: State of the Art Summary.
    Hepatology. 2015 Jun 10. doi: 10.1002/hep.27934.
    PubMed     Text format     Abstract available


  259. SIMON TG, Chung RT
    The new HCV bottleneck: Can delaying therapy be justified?
    Hepatology. 2015 Jun 8. doi: 10.1002/hep.27931.
    PubMed     Text format    


  260. SAXENA V, Nyberg L, Pauly M, Dasgupta A, et al
    Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis.
    Hepatology. 2015 Jun 1. doi: 10.1002/hep.27922.
    PubMed     Text format     Abstract available


  261. GREWAL P
    Reply to "does chronic hepatitis E virus infection exist in immunocompetent patients?".
    Hepatology. 2015;61:2117.
    PubMed     Text format    


  262. YOUNOSSI ZM, Stepanova M, Marcellin P, Afdhal N, et al
    Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Hepatology. 2015;61:1798-808.
    PubMed     Text format     Abstract available


    May 2015
  263. DICK TB, Lindberg LS, Ramirez DD, Charlton MR, et al
    A Clinician's Guide to Drug-Drug Interactions with Direct Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection.
    Hepatology. 2015 May 29. doi: 10.1002/hep.27920.
    PubMed     Text format     Abstract available


  264. TAWAR RG, Colpitts CC, Timm J, Fehm T, et al
    Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
    Hepatology. 2015 May 23. doi: 10.1002/hep.27906.
    PubMed     Text format     Abstract available


  265. SULTANIK P, Sogni P, Meritet J, Pol S, et al
    Patients with Chronic Hepatitis B should be screened for Hepatocellular Carcinoma Regardless of Liver Stiffness Measurement.
    Hepatology. 2015 May 23. doi: 10.1002/hep.27904.
    PubMed     Text format    


  266. KUSUMA A, Romero-Brey I, Berger C, Colpitts CC, et al
    Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication via blockage of membranous web formation.
    Hepatology. 2015 May 22. doi: 10.1002/hep.27913.
    PubMed     Text format     Abstract available


  267. KIM MN, Han KH, Kim SU
    Reply to "Patients with chronic hepatitis b should be screened for hepatocellular carcinoma regardless of liver stiffness measurement."
    Hepatology. 2015 May 20. doi: 10.1002/hep.27903.
    PubMed     Text format    


  268. LIU Z, Chen T, Wang Y, Zhang M, et al
    Age might confound the impact of the TM6SF2 E167K polymorphism on hepatic fibrosis in HCV- infected patients.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27899.
    PubMed     Text format    


  269. ROMEO S, Aghemo A, Berg T, Stickel F, et al
    TM6SF2 E167K and liver fibrosis in chronic hepatitis C.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27901.
    PubMed     Text format    


  270. CECCHERINI SILBERSTEIN F, Di Maio VC, Aragri M, Ciotti M, et al
    Hepatitis C Virus Gene Sequencing as a Tool for Precise Genotyping in the Era of New Direct Antiviral Agents.
    Hepatology. 2015 May 14. doi: 10.1002/hep.27895.
    PubMed     Text format    


  271. WONG GL, Tse YK, Wong VW, Fung TY, et al
    Long-term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B - a cohort study of 53,500 subjects.
    Hepatology. 2015 May 14. doi: 10.1002/hep.27894.
    PubMed     Text format     Abstract available


  272. TERRAULT N
    Difficult-to-Cure populations with chronic hepatitis C: Vanishing in the DAA era?
    Hepatology. 2015 May 12. doi: 10.1002/hep.27892.
    PubMed     Text format    


  273. ALQAHTANI SA, Afdhal N, Zeuzem S, Gordon S, et al
    Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27890.
    PubMed     Text format     Abstract available


  274. SINN DH, Lee J, Goo J, Kim K, et al
    Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27889.
    PubMed     Text format     Abstract available


  275. YOUNOSSI ZM, Jiang Y, Smith NJ, Stepanova M, et al
    Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
    Hepatology. 2015;61:1471-8.
    PubMed     Text format     Abstract available


    April 2015
  276. HSU PI, Lai KH, Cheng JS, Kao SS, et al
    Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area.
    Hepatology. 2015 Apr 9. doi: 10.1002/hep.27843.
    PubMed     Text format     Abstract available


  277. CHARLTON M
    Reply.
    Hepatology. 2015;61:1442-3.
    PubMed     Text format    


  278. ABDELRAHMAN T, Hughes J, Main J, McLauchlan J, et al
    Reply.
    Hepatology. 2015;61:1438.
    PubMed     Text format    


    February 2015
  279. TRINCHET JC, Bourcier V, Chaffaut C, Ait Ahmed M, et al
    Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27743.
    PubMed     Text format     Abstract available


    October 2014
  280. MULLER T, Wiese M, Berg T
    Reply: To PMID 23929603.
    Hepatology. 2014;60:1449-50.
    PubMed     Text format    


  281. MONDELLI MU
    The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
    Hepatology. 2014;60:1126-9.
    PubMed     Text format    


  282. KARKHANIS J, Verna EC, Chang MS, Stravitz RT, et al
    Reply: To PMID 23929808.
    Hepatology. 2014;60:1448.
    PubMed     Text format    


  283. FUJIWARA K, Yasui S, Yokosuka O
    Historical, present, and future significance of corticosteroid in the treatment of acute liver failure.
    Hepatology. 2014;60:1447-8.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: